Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Testosterone undecanoate | Testosterone undecanoate may increase the hypertensive activities of Ibopamine. |
| Meloxicam | The therapeutic efficacy of Ibopamine can be decreased when used in combination with Meloxicam. |
| Ziconotide | The risk or severity of CNS depression can be increased when Ibopamine is combined with Ziconotide. |
| Empagliflozin | Empagliflozin may increase the diuretic activities of Ibopamine. |
| Oliceridine | The therapeutic efficacy of Ibopamine can be decreased when used in combination with Oliceridine. |
| Vasopressin | Vasopressin may increase the hypertensive activities of Ibopamine. |
| Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Ibopamine. |
| Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ibopamine. |
| Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ibopamine. |
| Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ibopamine. |
| Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ibopamine. |
| Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ibopamine. |
| Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ibopamine. |
| NN344 | The therapeutic efficacy of NN344 can be decreased when used in combination with Ibopamine. |
| Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Ibopamine. |
| Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ibopamine. |
| Insulin argine | The therapeutic efficacy of Insulin argine can be decreased when used in combination with Ibopamine. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Ibopamine. |
| Insulin tregopil | The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Ibopamine. |
| Tretinoin | The risk or severity of elevated intracranial pressure can be increased when Ibopamine is combined with Tretinoin. |
| Tapentadol | The therapeutic efficacy of Ibopamine can be decreased when used in combination with Tapentadol. |
| Iloprost | Iloprost may increase the hypotensive activities of Ibopamine. |
| Insulin icodec | The therapeutic efficacy of Insulin icodec can be decreased when used in combination with Ibopamine. |